Enzyvant Sciences Logo White

Patient Focused. Results Driven.

Enzyvant Sciences Logo Mark

Our Mission

  • DEVELOP transformative therapies for rare diseases with high unmet needs
  • PURSUE innovative partnerships that create new opportunities in the rare disease field
  • DELIVER on our commitment to the patients, families, and communities we serve

Complete DiGeorge Syndrome

DiGeorge Syndrome (DGS) is a rare genetic disease caused by a defect in multiple genes on chromosome 22, leading to defective development of the pharyngeal pouch system and variety of consequences.

Farber Disease

Farber disease is an ultra-rare lysosomal storage disease caused by a mutation in both alleles of the ASAH1 gene, resulting in the deficiency of the lysosomal enzyme acid ceramidase.

Latest News

Enzyvant is proud to support Global Genes’ second annual RARE in the Square.
January 8-10, 2018
Coinciding with the annual J.P. Morgan Healthcare Conference.
Read More
Enzyvant Initiates Farber Disease Natural History Study
October `16, 2017
Global study aims to define the natural course of Farber disease
Read More
Enzyvant Receives Rare Designation
September 5, 2017
Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802
Read More
Enzyvant at PRES
September 14-17, 2017
Enzyvant will be hosting a lunch symposium on Farber disease at the PReS congress in Athens, Greece
Read More
Enzyvant at ICIEM
September 5-8, 2017
Enzyvant will be presenting two posters at the ICIEM conference in Rio de Janeiro, Brazil
Read More
Enzyvant Receives FDA Designations
April 17, 2017
Enzyvant receives FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for RVT-802.
Read More
February 28, 2017
Enzyvant is participating in rare disease day! Click below for a list of local events.
Read More
February 15, 2017
Enzyvant will be presenting two posters and an oral presentation at the WORLD Symposium in San Diego
Read More
January 9-11, 2017
Come meet us at “Rare in the Square” in Union Square, San Francisco
Read More
January 6, 2017
Enzyvant to develop a novel biologic therapy for the treatment of immunodeficiency in complete DiGeorge Syndrome
Read More
Dr. Alvin Shih Appointed CEO
November 1, 2016
Enzyvant has announced the appointment of Dr. Alvin Shih as Chief Executive Officer
Read More
Formation of Enzyvant
July 12, 2016
Roivant Sciences Ltd. and Plexcera Therapeutics LLC have announced the formation of Enzyvant Ltd.
Read More
Contact Us